Soleno Therapeutics (SLNO) Share-based Compensation: 2013-2024
Historic Share-based Compensation for Soleno Therapeutics (SLNO) over the last 12 years, with Dec 2024 value amounting to $100.0 million.
- Soleno Therapeutics' Share-based Compensation fell 60.08% to $204,000 in Q4 2019 from the same period last year, while for Dec 2019 it was $825,000, marking a year-over-year decrease of 36.54%. This contributed to the annual value of $100.0 million for FY2024, which is 1582.09% up from last year.
- Soleno Therapeutics' Share-based Compensation amounted to $100.0 million in FY2024, which was up 1,582.09% from $5.9 million recorded in FY2023.
- Soleno Therapeutics' 5-year Share-based Compensation high stood at $100.0 million for FY2024, and its period low was $1.5 million during FY2020.
- Over the past 3 years, Soleno Therapeutics' median Share-based Compensation value was $5.9 million (recorded in 2023), while the average stood at $36.2 million.
- In the last 5 years, Soleno Therapeutics' Share-based Compensation dropped by 23.33% in 2022 and then skyrocketed by 1,582.09% in 2024.
- Yearly analysis of 5 years shows Soleno Therapeutics' Share-based Compensation stood at $1.5 million in 2020, then skyrocketed by 120.00% to $3.3 million in 2021, then declined by 23.33% to $2.5 million in 2022, then skyrocketed by 134.98% to $5.9 million in 2023, then spiked by 1,582.09% to $100.0 million in 2024.